{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T13:05:13Z","timestamp":1652360713117},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,1,11]],"date-time":"2015-01-11T00:00:00Z","timestamp":1420934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00330-014-3579-x","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T19:41:47Z","timestamp":1420918907000},"page":"1801-1813","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Yu-Cheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsian-He","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chou","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jui","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Hsiung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chih","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Wang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,11]]},"reference":[{"key":"3579_CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"3579_CR2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMct0807960","volume":"364","author":"VD Cataldo","year":"2011","unstructured":"Cataldo VD, Gibbons DL, P\u00e9rez-Soler R, Quint\u00e1s-Cardama A (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364:947\u2013955","journal-title":"N Engl J Med"},{"key":"3579_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","volume":"353","author":"MS Tsao","year":"2005","unstructured":"Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer\u2014molecular and clinical predictors of outcome. N Engl J Med 353:133\u2013144","journal-title":"N Engl J Med"},{"key":"3579_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2006.07.3585","volume":"25","author":"LV Sequist","year":"2007","unstructured":"Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587\u2013595","journal-title":"J Clin Oncol"},{"key":"3579_CR5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1158\/1078-0432.CCR-10-2158","volume":"17","author":"R Rosell","year":"2011","unstructured":"Rosell R, Molina MA, Costa C et al (2011) Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17:1160\u20131168","journal-title":"Clin Cancer Res"},{"key":"3579_CR6","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","volume":"30","author":"EE Schaake","year":"2012","unstructured":"Schaake EE, Kappers I, Codrington HE et al (2012) Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol 30:2731\u20132738","journal-title":"J Clin Oncol"},{"key":"3579_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2010.10.019","volume":"73","author":"HY Lee","year":"2011","unstructured":"Lee HY, Lee KS, Ahn MJ et al (2011) New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 73:63\u201369","journal-title":"Lung Cancer"},{"key":"3579_CR8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"3579_CR9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","volume":"45","author":"LI Lin","year":"1989","unstructured":"Lin LI (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255\u2013268","journal-title":"Biometrics"},{"key":"3579_CR10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307\u2013310","journal-title":"Lancet"},{"key":"3579_CR11","first-page":"451","volume":"4","author":"PT Lavin","year":"1981","unstructured":"Lavin PT (1981) An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 4:451\u2013457","journal-title":"Cancer Clin Trials"},{"key":"3579_CR12","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/jnci\/djm158","volume":"99","author":"TG Karrison","year":"2001","unstructured":"Karrison TG, Maitland ML, Stadler WM, Ratain MJ (2001) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455\u20131461","journal-title":"J Natl Cancer Inst"},{"key":"3579_CR13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.urolonc.2011.08.010","volume":"31","author":"AD Smith","year":"2013","unstructured":"Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2013) Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. Urol Oncol 31:1283\u20131291","journal-title":"Urol Oncol"},{"key":"3579_CR14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/annonc\/mdr350","volume":"23","author":"C Suzuki","year":"2012","unstructured":"Suzuki C, Blomqvist L, Sundin A et al (2012) The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 23:948\u2013954","journal-title":"Ann Oncol"},{"key":"3579_CR15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1148\/radiol.12121106","volume":"266","author":"KM Jang","year":"2013","unstructured":"Jang KM, Kim SH, Lee SJ et al (2013) Added value of diffusion-weighted MR imaging in the diagnosis of ampullary carcinoma. Radiology 266:491\u2013501","journal-title":"Radiology"},{"key":"3579_CR16","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00330-012-2496-0","volume":"22","author":"G Somoye","year":"2012","unstructured":"Somoye G, Harry V, Semple S et al (2012) Early diffusion weighted magnetic resonance imaging can predict survival in women with locally advanced cancer of the cervix treated with combined chemo-radiation. Eur Radiol 22:2319\u20132327","journal-title":"Eur Radiol"},{"key":"3579_CR17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2214\/AJR.08.1367","volume":"193","author":"J Wang","year":"2009","unstructured":"Wang J, Wu N, Cham MD et al (2009) Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 193:1090\u20131096","journal-title":"AJR Am J Roentgenol"},{"key":"3579_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"3579_CR19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3579_CR20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1148\/radiol.2512081403","volume":"251","author":"S Stacchiotti","year":"2009","unstructured":"Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment\u2013pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447\u2013456","journal-title":"Radiology"},{"key":"3579_CR21","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/sj.bjc.6601843","volume":"90","author":"JE Husband","year":"2004","unstructured":"Husband JE, Schwartz LH, Spencer J et al (2004) Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 90:2256\u20132260","journal-title":"Br J Cancer"},{"key":"3579_CR22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3348\/kjr.2010.11.6.618","volume":"11","author":"HY Lee","year":"2010","unstructured":"Lee HY, Lee KS, Hwang HS et al (2010) Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J Radiol 11:618\u2013626","journal-title":"Korean J Radiol"},{"key":"3579_CR23","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3348\/kjr.2012.13.6.702","volume":"13","author":"YN Kim","year":"2012","unstructured":"Kim YN, Lee HY, Lee KS et al (2012) Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? Korean J Radiol 13:702\u2013710","journal-title":"Korean J Radiol"},{"key":"3579_CR24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/JTO.0b013e3181a94a2f","volume":"4","author":"K Tsujino","year":"2009","unstructured":"Tsujino K, Kawaguchi T, Kubo A et al (2009) Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 4:994\u20131001","journal-title":"J Thorac Oncol"},{"key":"3579_CR25","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","volume":"22","author":"MJ Ratain","year":"2004","unstructured":"Ratain MJ, Eckhardt SG (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22:4442\u20134445","journal-title":"J Clin Oncol"},{"key":"3579_CR26","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753\u20131759","journal-title":"J Clin Oncol"},{"key":"3579_CR27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.2007.13.3652","volume":"26","author":"S Sathornsumetee","year":"2008","unstructured":"Sathornsumetee S, Cao Y, Marcello JE et al (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271\u2013278","journal-title":"J Clin Oncol"},{"key":"3579_CR28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2007.13.8099","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A, Hedrick EE, Mass RD et al (2008) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183\u2013189","journal-title":"J Clin Oncol"},{"key":"3579_CR29","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1378\/chest.120.5.1584","volume":"120","author":"K Junker","year":"2001","unstructured":"Junker K, Langner K, Klinke F, Bosse U, Thomas M (2001) Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest 120:1584\u20131591","journal-title":"Chest"},{"key":"3579_CR30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF01192200","volume":"123","author":"K Junker","year":"1997","unstructured":"Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, M\u00fcller KM (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469\u2013477","journal-title":"J Cancer Res Clin Oncol"},{"key":"3579_CR31","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/cncr.24151","volume":"115","author":"MJ Park","year":"2009","unstructured":"Park MJ, Lee J, Hong JY et al (2009) Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 115:1518\u20131530","journal-title":"Cancer"},{"key":"3579_CR32","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse M, Burzykowski T, Carroll K et al (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218\u20135224","journal-title":"J Clin Oncol"},{"key":"3579_CR33","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","volume":"25","author":"PA Tang","year":"2007","unstructured":"Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562\u20134568","journal-title":"J Clin Oncol"},{"key":"3579_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pst.251","volume":"6","author":"KJ Carroll","year":"2007","unstructured":"Carroll KJ (2007) Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 6:99\u2013113","journal-title":"Pharm Stat"},{"key":"3579_CR35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10147-009-0885-4","volume":"14","author":"Q Shi","year":"2009","unstructured":"Shi Q, Sargent DJ (2009) Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol 14:102\u2013111","journal-title":"Int J Clin Oncol"},{"key":"3579_CR36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1471-2407-7-106","volume":"7","author":"VA Levin","year":"2007","unstructured":"Levin VA, Ictech S, Hess KR (2007) Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer 7:106","journal-title":"BMC Cancer"},{"key":"3579_CR37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1684\/bdc.2009.0858","volume":"96","author":"N Methy","year":"2009","unstructured":"Methy N, Bedenne L, Bonnetain F (2009) Validation of surrogate endpoints in digestive oncology. Bull Cancer 96:591\u2013595","journal-title":"Bull Cancer"},{"key":"3579_CR38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1148\/radiographics.17.6.9397450","volume":"17","author":"KS Lee","year":"1997","unstructured":"Lee KS, Kim Y, Han J, Ko EJ, Park CK, Primack SL (1997) Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings. Radiographics 17:1345\u20131357","journal-title":"Radiographics"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-014-3579-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-014-3579-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-014-3579-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T14:34:35Z","timestamp":1566225275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-014-3579-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["3579"],"URL":"https:\/\/doi.org\/10.1007\/s00330-014-3579-x","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,11]]}}}